Pegozafermin (BIO89-100)
Metabolic dysfunction-associated steatohepatitis (MASH)
Key Facts
About 89bio
89bio is a clinical-stage biotech focused on liver and cardiometabolic diseases, leveraging fibroblast growth factor 21 (FGF21) biology. Its lead asset, pegozafermin, is an engineered FGF21 analog in Phase 3 trials for MASH and SHTG, targeting significant unmet medical needs. In September 2025, the company announced an agreement to be acquired by Roche, marking a pivotal strategic exit.
View full company profileAbout 89bio
89bio is a clinical-stage biotech focused on liver and cardiometabolic diseases, leveraging fibroblast growth factor 21 (FGF21) biology. Its lead asset, pegozafermin, is an engineered FGF21 analog in Phase 3 trials for MASH and SHTG, targeting significant unmet medical needs. In September 2025, the company announced an agreement to be acquired by Roche, marking a pivotal strategic exit.
View full company profileTherapeutic Areas
Other Metabolic dysfunction-associated steatohepatitis (MASH) Drugs
| Drug | Company | Phase |
|---|---|---|
| NGM831 (MK-3655) | NGM Biopharmaceuticals | Phase 2b |
| Icosabutate | NorthSea Therapeutics | Phase 3 |
| Oxy210 | MAX BioPharma | Preclinical |
| NA-941 | Biomed | Phase 2A |
| PRO-MSH-001 | ProdIgY Biotech | Discovery |
| Undisclosed MASH Program | Syndya Therapeutics | Discovery |
| Partnered Program | Cellarity | Pre-clinical |
| Lanifibranor | Hepalys | Phase 1 |
| IW-601 | ImmuneWalk Therapeutics | Preclinical |
| ION224 (IONIS-DGAT2Rx) | Ionis Pharmaceuticals | Phase 2b |
| ALG-055009 | Aligos Therapeutics | Phase 2 |
| CM-101 | Chemomab Therapeutics | Phase 2a |